ReviewCurrent HIV/AIDS reports2023
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?
Review in Current HIV/AIDS reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- A Systematic Review of Factors Associated with COVID-19 Vaccine Uptake, Hesitancy, and Acceptability Among Adults with HIV: Implications for Integrating COVID-19 Immunization into HIV Care.AIDS patient care and STDs · 2024Pooled it
- Association of Prior SARS-CoV-2 Infection with Immune Activation in Virally Suppressed People Living with HIV.Microorganisms · 2026Article
- High risk of COVID-19 mortality in people living with advanced HIV disease in South Africa: A retrospective cohort study.Medicine · 2026Article
- Associations between serological evidence of SARS-CoV-2 infection and longitudinal pulmonary outcomes among people with HIV: analysis of the MACS/WIHS combined cohort study (MWCCS).Respiratory research · 2026Article
- The interplay between recovery and immunity in infectious and non-communicable diseases.Frontiers in cellular and infection microbiology · 2026Review
- Exploring the Relationship Between Comorbidities and Prolonged Viral Shedding in COVID-19: A Cycle Threshold Value-Based Investigation.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Study on the spatial-temporal evolution and influencing factors of AIDS incidence in China from 2006 to 2022.BMC infectious diseases · 2025Article
- Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV.Journal of translational medicine · 2025Article
- Review
- Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.Nature communications · 2025Article
- Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infection.AIDS (London, England) · 2025Article
- Immune Response Against Recent Omicron Sub-Lineages in Persons with HIV Receiving a Protein-Based or mRNA XBB.1.5 SARS-CoV-2 Booster Vaccine.International journal of molecular sciences · 2025Article
- Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV.Communications medicine · 2025Article
- Macrovascular Function in People with HIV After Recent SARS-CoV-2 Infection.Journal of vascular diseases · 2025Article
- Difference of SARS-CoV-2 infection and influence factors between people with and without HIV infection.BMC public health · 2025Article
- Are older adults living with HIV more susceptible to omicron infection compared to their HIV-negative peers in China: a cross-sectional study.Frontiers in public health · 2025Article
- Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal study.Medical microbiology and immunology · 2024Article
- Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS-CoV-2 Main Protease Inhibitors.Chemistry & biodiversity · 2024Article
- Article
- Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in People Living with HIV (PLWH).Vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHIV/AIDS and COVID-19 have been the major pandemics overwhelming our times. Given the enduring immune disfunction featuring people living with HIV (PLWH) despite combination antiretroviral therapy (cART), concerns for higher incidence and severity of SARS-CoV-2 infection as well as for suboptimal responses to the newly developed vaccines in this population arose early during the pandemics. Herein, we discuss the complex interplay between HIV and SARS-CoV-2, with a special focus on the immune responses to SARS-CoV-2 natural infection and vaccination in PLWH. RECENT
findingsOverall, current literature shows that COVID-19 severity and outcomes may be worse and immune responses to infection or vaccination lower in PLWH with poor CD4 + T-cell counts and/or uncontrolled HIV viremia. Data regarding the risk of post-acute sequelae of SARS-CoV-2 infection (PASC) among PLWH are extremely scarce, yet they seem to suggest a higher incidence of such condition. Scarce immunovirological control appears to be the major driver of weak immune responses to SARS-CoV-2 infection/vaccination and worse COVID-19 outcomes in PLWH. Therefore, such individuals should be prioritized for vaccination and should receive additional vaccine doses. Furthermore, given the potentially higher risk of developing long-term sequelae, PLWH who experienced COVID-19 should be ensured a more careful and prolonged follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.